Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis

Trial Profile

Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Familial adenomatous polyposis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2017 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
    • 26 Sep 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.
    • 26 Sep 2017 Planned initiation date changed from 31 Jan 2017 to 13 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top